Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa

Antimicrob Resist Infect Control. 2020 Aug 5;9(1):124. doi: 10.1186/s13756-020-00793-8.

Abstract

Fluoroquinolone resistance in Pseudomonas aeruginosa typically arises through site-specific mutations and overexpression of efflux pumps. In this study, we investigated the dynamics of different resistance mechanisms in P. aeruginosa populations that have evolved under fluoroquinolone pressure, as well as the interactions between these mechanisms in evolutionary trajectories. Bacteria of strain ATCC27853 were selected under different concentrations of ciprofloxacin and levofloxacin for six parallel lineages, followed by amplification of four target genes in the quinolone-resistance determining region (QRDR) and Sanger sequencing to identify the mutations. The expression of four efflux pump proteins was evaluated by real-time polymerase chain reaction using the relative quantitation method, with the ATCC27853 strain used as a control. We found that ciprofloxacin killed P. aeruginosa sooner than did levofloxacin. Further, we identified five different mutations in three subunits of QRDRs, with gyrA as the main mutated gene associated with conferring fluoroquinolone resistance. Additionally, we found a larger number of mutations appearing at 2 mg/L and 4 mg/L of ciprofloxacin and levofloxacin, respectively. Moreover, we identified the main efflux pump being expressed as MexCD-OprJ, with initial overexpression observed at 0.25 mg/L and 0.5 mg/L of ciprofloxacin and levofloxacin, respectively. These results demonstrated gyrA83 mutation and MexCD-OprJ overexpression as the primary mechanism conferring ciprofloxacin and levofloxacin resistance in P. aeruginosa. In addition, we also show that ciprofloxacin exhibited a stronger ability to kill the bacteria while potentially rendering it more susceptible to resistance.

Keywords: Ciprofloxacin; Efflux pumps; Fluoroquinolone; Levofloxacin; Pseudomonas aeruginosa.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Ciprofloxacin / pharmacology
  • Drug Resistance, Bacterial / genetics*
  • Fluoroquinolones / classification
  • Fluoroquinolones / pharmacology*
  • Levofloxacin / pharmacology
  • Membrane Transport Proteins / genetics
  • Microbial Sensitivity Tests
  • Mutation
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / genetics*

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones
  • Membrane Transport Proteins
  • Ciprofloxacin
  • Levofloxacin